12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 17 June 2024Expected publication date: 12 February 2025
Anaphylaxis: assessment and referral after emergency treatment (CG134)Product type:GuidanceProgramme:Clinical guidelineLast updated: 24 August 2020Published: 14 December 2011
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Cryotherapy for chronic rhinitis (IPG771)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 14 September 2023
Drug allergy: diagnosis and management (CG183)Product type:GuidanceProgramme:Clinical guidelinePublished: 3 September 2014
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years TS ID 11885Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Food allergy in under 19s: assessment and diagnosis (CG116)Product type:GuidanceProgramme:Clinical guidelinePublished: 23 February 2011
ImmunoCAP ISAC 112 for multiplex allergen testing (DG24)Product type:GuidanceProgramme:Diagnostics guidancePublished: 18 May 2016
Intranasal phototherapy for allergic rhinitis (IPG616)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 13 June 2018
Omalizumab for treating severe persistent allergic asthma (TA278)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palforzia for treating peanut allergy in children and young people (TA769)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Pharmalgen for the treatment of bee and wasp venom allergy (TA246)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2012
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal) (TA834)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 October 2022
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
The Airsonett temperature-controlled laminar airflow device for persistent allergic asthma (MIB8)Product type:AdviceProgramme:Medtech innovation briefingPublished: 11 August 2014
Thora-3Di for assessing asthma in children (MIB122)Product type:AdviceProgramme:Medtech innovation briefingPublished: 2 October 2017
Transforming the care of children and young people in London with asthma: Development of the London Asthma StandardsProduct type:Shared learningPublished: 4 February 2021
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC